Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 10/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619769 | 0.88 | FGFR1 (0.45) | FGFR1FLT1EGFRGAKKDM1A | |
| SCHEMBL25827013 | 0.83 | KDM1A (0.50) | FGFR1FLT1EGFRGAKKDM1A | |
| SCHEMBL16083527 | 0.82 | EHMT2 (0.49) | FGFR1FLT1EGFRKDRRET | |
| SCHEMBL14310926 | 0.82 | EHMT2 (0.49) | FGFR1FLT1EGFRKDRRET | |
| SCHEMBL21753968 | 0.82 | PDGFRB (0.47) | FGFR1FLT1EGFRGAK | |
| SCHEMBL29492471 | 0.82 | PDGFRB (0.55) | EGFRGAK | |
| SCHEMBL165285 | 0.82 | PDGFRB (0.55) | EGFRGAK | |
| SCHEMBL29736268 | 0.81 | EHMT2 (0.60) | FGFR1FLT1EGFRGAKKDM1A | |
| SCHEMBL30465547 | 0.81 | FLT1 (0.54) | FGFR1FLT1EGFRGAKKDM1A | |
| SCHEMBL2748495 | 0.81 | FLT1 (0.54) | FGFR1FLT1EGFRGAKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | FGFR1 12/4885FLT1 5/4885EGFR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.